Facilities

Fujifilm expands its gene therapy drug CDMO business

07-Oct-2020 By Jane Byrne

Fujifilm is boosting its gene therapy offering, taking the first steps to expand its viral vector contract development and manufacturing organization (CDMO) services to Europe, at the site of Fujifilm Diosynth Biotechnologies (FDB) in the North East of...

COVID-19 vaccine manufacturing centre gains MHRA approval; ready to produce tens of millions of doses in the UK

06-Oct-2020 By Rachel Arthur

The UK’s Vaccines Manufacturing & Innovation Centre (VMIC) announces that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved the second of two GMP COVID-19 vaccine manufacturing suites located at Oxford Biomedica's...

CPhI Festival of Pharma

CPhl event to draw attention to M&A activity in gene and cell sector

01-Oct-2020 By Jane Byrne

The recent M&A trend in the cell and gene therapy space will be put under the spotlight at the CPhl Festival of Pharma.

‘Viral vector production demand will ultimately exceed the current global capacity’

23-Sep-2020 By Jane Byrne

Catalent recently announced that it is investing US$130m in an expansion project at its viral vector manufacturing facility located in Harmans, Maryland, with five new manufacturing suites set to respond to a growing customer pipeline and market demand.

Epilepsy gene therapy candidate moves closer to clinical study phase

17-Sep-2020 By Jane Byrne

Gene therapy developer, CombiGene, and CDMO, Cobra Biologics, have signed off on a deal to secure Good Manufacturing Practice (GMP) production of two essential plasmids needed for the manufacture of CombiGene's gene therapy, CG01.

Thermo Fisher addresses the growing need for more flexible, scalable biologics development

15-Sep-2020 By Jane Byrne

Thermo Fisher Scientific has opened a new bioprocessing collaboration center (BCC) adjacent to its biologics manufacturing facility in St Louis, Missouri.

Catalent secures further Covid-19 vaccine business with AstraZeneca

01-Sep-2020 By Jane Byrne

Catalent is to provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19 vaccine, AZD1222.

Fujifilm to produce COVID-19 vaccines, BARDA speeds up capacity boost

03-Aug-2020 By Ben Hargreaves

US BARDA drafts Fujifilm Diosynth into its vaccine production effort, offering to also accelerate capacity expansion.

The growth of the UK’s ‘golden triangle’

22-Jul-2020 By Ben Hargreaves

Research outlines the pace of growth in the UK’s biohub and how it will progress towards 2050.

Ireland calls attention to cell and gene infrastructure

22-Jul-2020 By Ben Hargreaves

A report by IDA outlines investment made by biopharma into cell and gene development and manufacturing capabilities.

MassBio wants improved manufacturing to maintain biohub position

22-Jul-2020 By Ben Hargreaves

The organization calls for capabilities to manufacture advanced therapeutics, such as cell and gene therapies.

Catalent to invest $30m on clinical manufacturing site in France

21-Jul-2020 By Ben Hargreaves

The company invests into its clinical biologics formulation development and drug fill-finish services.

Rentschler and Vetter cooperate to integrate services

09-Jul-2020 By Ben Hargreaves

The CDMOs will launch pilot projects to determine where collaboration may help streamline drug development.

Emergent signs $480m, five-year vaccine deal with J&J

07-Jul-2020 By Ben Hargreaves

Emergent will provide contract development and manufacturing services for J&J’s potential COVID-19 vaccine.

Regeneron COVID-19 antibody cocktail enters late-stage trials

07-Jul-2020 By Ben Hargreaves

Regeneron’s potential coronavirus treatment enters Phase III and US government provides capital injection for manufacture.